BIONEER CORPORATION

Bioneer Participates in MEDICA 2024, Accelerating Entry into the Global HIV Procurement Market

- Set to participate in public bids for viral load testing with its WHO-PQ certified HIV-1 VL Kit

- Secured numerous new distributors across Europe, MENA, Africa, and Asia

Bioneer announced on the 15th that it successfully concluded its participation in MEDICA 2024, the world’s largest B2B medical device exhibition, held in Düsseldorf, Germany, from November 11 to 14.

The event attracted approximately 83,000 visitors from 70 countries, showcasing a wide range of innovative products. Bioneer introduced its WHO-PQ-certified HIV-1 VL Kit, along with its ExiStation™ System and all compatible IRON-qPCR™ assays. The company also strengthened collaborations with existing distributors and partners in key markets, including Europe, the Middle East, and North Africa, while discussing opportunities with new potential partners.

According to 2023 WHO data, approximately 39.9 million people worldwide live with HIV, with two-thirds concentrated in Africa and more than half of new infections occurring in the region. Bioneer’s recently WHO-PQ-certified HIV-1 Quantitative Diagnostic Kit has opened doors for participation in public procurement tenders in major affected countries, such as South Africa. This kit is essential for monitoring viral suppression, helping patients maintain a normal lifespan. Bioneer aims to expand its global market share while providing affordable solutions to African patients, contributing to the eradication of infectious diseases.

At the exhibition, Bioneer also showcased its IRON-qPCR™ system, which has received European certification. This system supports syndromic diagnostic testing, detecting up to 40 pathogens within 30–40 minutes, drawing significant interest from attendees. Other highlighted products included the RFIA Kit (for tuberculosis and multidrug-resistant tuberculosis, as well as secondary anti-tuberculosis resistance genes), the AMR&ID Kit (detecting seven major sepsis-causing pathogens and 17 antibiotic resistance genes from blood cultures), the CRE Kit (detecting five major carbapenem-resistant superbugs in Enterobacteriaceae), the RV Kit (detecting four types of respiratory viruses), COVID-19 tests, and upcoming products such as the STI 12 Kit (detecting 12 types of sexually transmitted infections) and the MBD Kit (for mosquito-borne diseases).

A Bioneer representative stated, “Through this exhibition, we successfully secured numerous new distributors across Europe, MENA, Africa, and Asia.” The representative added, “Based on our meetings with Global Fund representatives and international public procurement organizations during the event, we plan to pursue public tenders for viral load testing using our WHO-PQ-certified HIV Kit. We will continue to strengthen global partnerships by delivering reliable diagnostic solutions.”